VesiVax Vaccine Formulation Against Neisseria gonorrhoeae

针对淋病奈瑟氏菌的 VesiVax 疫苗配方

• 批准号: 10385208
• 负责人: Gary Fujii
• 金额: $ 29.98万
• 依托单位: MOLECULAR EXPRESS, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-18 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10385208
• 关键词: Adjuvant; Agonist; Agreement; Animals; Antibiotic Resistance; Antibodies; Antigen Targeting; Antigens; Binding Proteins; Case-Control Studies; Development; Diagnosis; Double-Stranded RNA; Evaluation; Formulation; Goals; Gold; Gonorrhea; HIV; Homologous Gene; Hydrophobicity; IgG1; Immune response; Immunity; Immunoglobulin A; Immunoglobulin M; Immunologics; Individual; Infection; Interleukin-12; Knowledge; Laboratories; Lead; Ligands; Link; Lipid A; Lipid Bilayers; Lipids; Liposomes; Membrane; Modeling; Molecular; Molecular Conformation; Mus; Nature; Neisseria gonorrhoeae; Neisseria meningitidis; Peptides; Phase; Preparation; Prevention; Procedures; Process; Protein Engineering; Proteins; Public Health; Recombinant Proteins; Recombinants; Reproductive Tract Infections; Research; Risk; Serogroup B Neisseria meningitidis; Services; Sexually Transmitted Diseases; Small Business Innovation Research Grant; Surface; System; TLR4 gene; Technology; Testing; United States; Universities; Vaccinated; Vaccines; Vesicle; Virus Diseases; Women' s Group; amphiphilicity; bactericide; base; design; dosage; epidemiologic data; flexibility; gonorrhea vaccine; immunogenicity; lead candidate; liposomal delivery; mouse model; nanoparticulate; novel; phase 2 study; professor; protective effect; public health relevance; reproductive tract; vaccine access; vaccine efficacy; vaccine formulation; vaccine immunogenicity; viral transmission

Project Summary The principal goal of this project is to develop a VesiVax®-based vaccine against Neisseria gonorrhoeae (Ng). The studies proposed in this SBIR Phase I application will be focused on co-formulating an newly identified surface-displayed outer membrane Ng protein, MtrE, with various immunostimulatory adjuvant molecules (IAMs) in the VesiVax® liposomal platform. We will characterize the immunogenicity of these VesiVax®-MtrE-IAM formulations in mice, and select for the best candidates to be further evaluated in a novel mouse upper reproductive tract Ng infection model. These studies will elucidate the immunological profile in a vaccine that will correlate with protective immunity against Ng.

项目总结